Interleukin production in juvenile chronic arthritis SIR, We read with interest the paper by Gilman and coworkers who showed that in rats with adjuvant-induced arthritis peritoneal macrophages produce higher amounts of interleukin 1 (IL-1), while splenic T cells produce less interleukin 2 (IL-2) than controls.' We found comparable results when studying interleukin production by peripheral blood mononuclear cells in children with juvenile chronic arthritis (JCA) (unpublished data). We investigated a total of 28 children with JCA ranging in age from 3 to 16 years. Ten presented a systemic form, six a polyarticular, and twelve a pauciarticular form. Patients were divided according to clinical activity of the disease into three groups: active disease, partial remission, and remission. Twentyone age matched healthy children served as controls. Peripheral blood monocytes were isolated by adherence and stimulated in vitro with lipopolysaccharide: IL-1 in the supernatants was assessed by a thymocyte coproliferation assay. Peripheral blood lymphocytes were stimulated in vitro with phytohaemagglutinin, and IL-2 in the supernatants was quantified by an IL-2-dependent cell line.
findings could not be explained by concurrent treatment. The greater IL-1 production was more evident in patients with active disease, whereas production of IL-2 was lowest in patients with complete remission. No major differences were observed among the three JCA subtypes. The similarities between our findings in JCA patients and the findings of Gilman et al.t in adjuvant-induced arthritis suggest that modulation of interleukin production may be of relevance in the pathogenesis of JCA, and, together with the previous finding of reduced production of IL-2 in adult rheumatoid arthritis and systemic lupus erythematosus, 2 (RA)' 2 but has not previously been reported after sulphasalazine (SASP) therapy. SASP is now becoming established as an effective second-line drug in RA with apparently few serious side effects. -5 We report a patient in whom both hypogammaglobulinaemia and thrombocytopenia together with oedema and rash occurred with this drug.
Case history
A 61-year-old lady with seropositive, erosive nodular RA had an excellent clinical response to SASP 2 g daily, with a concomitant fall in her erythrocyte sedimentation rate (ESR). Treatment was continued for 18 weeks at which time she developed clinical and laboratory abnormalities. She presented with oedema and a rash on her face and lower legs. The rash was erythematous, pruritic, and non-purpuric. The platelet count had fallen to 76 000/mm3
(76x 109/1) (Fig. 1) , but white blood cell count was normal.
IgG had fallen from the initial level of 8 19 to 4-95 g/l. IgA from 2 16 to 0-39 g/l, IgM from 2-75 to 0-34 g/l, and the Rose-Waaler titre from 1/156 to 1/8, and serum albumin was unchanged. She had no proteinuria. Sulphasalazine was stopped, and one week later both rash and oedema had subsided. During the following three weeks the serum IgG level fell further to 1-9 g/l, though serum IgA rose to 0-63 g/l and IgM to 0-47 g/l. Despite the immunodeficiency and her past history of chest infections she continued to be well and her arthritis remained in remission. After this the serum immunoglobulin levels and platelet count increased and at three months all were normal (Fig. 1) . She continued the same non-steroidal anti-inflammatory agent (fenbufen) throughout the time reported. Hypogammaglobulinaemia, thrombocytopenia, oedema, and a non-purpuric rash occurred after 18 weeks of SASP therapy. These resolved after stopping the drug, thus implicating SASP as a causative factor. Our patient had previously taken various non-steroidal antiinflammatory drugs without side effects but no second-line agents and continued fenbufen throughout the time reported. Thrombocytopenia is a recognised complication of other second-line drugs. including gold and penicillamine. It has been reported (as part of pancytopenia) in association with SASP therapy in inflammatory bowel disease" 7 but not in RA. It is thought to be due to the sulphapyridine moietN. Hypogammaglobulinaemia has 
